-
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
Friday, June 10, 2011 - 11:00am | 323Insmed Incorporated (Nasdaq: INSM) today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACE (liposomal amikacin for inhalation) in cystic fibrosis patients with Pseudomonas lung infections. The data were presented at...
-
Options Brief: Aastrom Biosciences, Inc.
Friday, June 10, 2011 - 10:25am | 80Shares of Aastrom Biosciences, Inc. (NASDAQ: ASTM) are lower on the session by 1.32%, trading at $2.98. Overall call volume is now running at 3.96x the daily average, with 0% of all calls traded being purchases on the offer. 2,400 contracts have traded on the session so far. Aastrom Biosciences...
-
Goldman Sachs Closes Out Two Losing Trades
Friday, June 10, 2011 - 9:33am | 192Goldman Sachs is out with a research note this morning, where it issues closing trade alerts for Johnson & Johnson (NYSE: JNJ) and Vertex Pharmaceuticals (NASDAQ: VRTX). The analysts recommend that investors close out their trade recommendation to buy the $67.50 July calls in Johnson &...
-
PharmAthene Announces $6.5 Million Registered Direct Offering
Friday, June 10, 2011 - 9:23am | 104PharmAthene, Inc. (NYSE: PIP) announced today that it has entered into subscription agreements with certain institutional investors to sell approximately $6.5 million of its common stock and warrants in a registered direct offering. Under the terms of the subscription agreements, at closing,...
-
J.P. Morgan Gives Update On VRTX
Friday, June 10, 2011 - 8:12am | 276J.P. Morgan is maintaining its Neutral rating and its $53 price target on Vertex Pharmaceuticals (NASDAQ: VRTX) following new data released by the company at the European Cystic Fibrosis Conference. According to J.P. Morgan, “We are attending the European Cystic Fibrosis (CF) conference in Germany...
-
Bank of America Merrill Lynch Maintains Buy on Regeneron Pharmaceuticals
Friday, June 10, 2011 - 8:10am | 113Bank of America Merrill Lynch is out with its report today on Regeneron Pharmaceuticals (NASDAQ: REGN), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "We rate REGN shares Buy, owing to a rich and undervalued pipeline of biologic therapies. Our DCF-derived PO of $65...
-
Ziopharm Reports Initial Positive Data Presented at 2011 Asco, Zin-cti-001 Well Tolerated
Friday, June 10, 2011 - 7:44am | 666ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Douglas J. Schwartzentruber, MD, FACS, of the Indiana University Health Goshen Center for Cancer Care, presented initial positive clinical results from the first-ever treatment demonstrating control over transgene encoding of a therapeutic...
-
Piper Jaffray Initiates an Overweight Rating and $23 PT on Incyte
Friday, June 10, 2011 - 7:20am | 98According to a recent report, Piper Jaffray has initiated an Overweight rating and $23.00 price target on Incyte (NASDAQ: INCY). The company also expects ruxolitinib to grow beyond CYT387 launch; however, the current price target assumes no growth after the 2015-16 launch. In the report, Piper...
-
Piper Jaffray Initiates Incyte Corporation At Overweight, $23 PT
Friday, June 10, 2011 - 6:09am | 25Piper Jaffray has initiated coverage on Incyte Corporation (NASDAQ: INCY) with an Overweight rating and $23 price target.
-
Stock Picks and Trade Ideas for Friday, June 10
Thursday, June 9, 2011 - 5:04pm | 1789( click to enlarge ) Elan Corporation, plc (ADR) (NYSE:ELN) broke out today and traded nearly 2x normal daily volume. The stock has the potential to make a big run on Friday, so keep a close eye on ELN and don't miss the trade. From the technical analysis perspective, the outlook for Elan...
-
Chelsea Therapeutics Announces New Data from Northera Phase III Program in Neurogenic Orthostatic Hypotension
Thursday, June 9, 2011 - 4:18pm | 408Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) announced that new data from Phase III trials in symptomatic neurogenic orthostatic hypotension demonstrating the activity and tolerability of NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, were presented at the...
-
OnDose Study Demonstrates Need for Improved Dosing Approach for Colorectal Cancer Patients
Thursday, June 9, 2011 - 4:06pm | 128Myriad Genetics (Nasdaq: MYGN) announced today that a study published in Clinical Colorectal Cancer entitled "Body Surface Area-based Dosing of 5-Fluoruracil Results in Extensive Inter-individual Variability in 5-Fluroruracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens" demonstrated...
-
Puts Purchased on Regeneron Pharmaceuticals
Thursday, June 9, 2011 - 3:27pm | 115Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) are lower on the session by 1.06%, currently trading at $56.16. The stock has been moving largely higher over the past four months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name...
-
Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation
Thursday, June 9, 2011 - 2:40pm | 102Emergent BioSolutions Inc. (NYSE: EBS) announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration. The vaccine candidate, also known as AV7909, consists of BioThrax in combination with a novel...
-
Options Brief: Amylin Pharmaceuticals
Thursday, June 9, 2011 - 12:52pm | 77Shares of Amylin Pharmaceuticals (NASDAQ: AMLN) are lower on the session by 0.15%, trading at $12.91. Overall call volume is now running at 4.41x the daily average, with 61% of all calls traded being purchases on the offer. 3,634 contracts have traded on the session so far. Amylin...